Abstract
Perioperative morbidity and mortality are frequently cardiac in origin. Many studies have prospectively attempted to define risk factors for cardiac ischemic events. Although we can now identify high-risk patients, optimal cardioprotective management strategies remain unclear. Treatment with beta-adrenergic antagonists decreases myocardial oxygen consumption and is generally well tolerated. This article reviews the physiologic and clinical basis for using these agents as prophylaxis against cardiovascular events in high-risk surgical patients.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Adrenergic beta-Antagonists / administration & dosage*
-
Adrenergic beta-Antagonists / adverse effects
-
Animals
-
Arrhythmias, Cardiac / mortality
-
Arrhythmias, Cardiac / prevention & control*
-
Heart Failure / mortality
-
Heart Failure / prevention & control*
-
Humans
-
Myocardial Infarction / mortality
-
Myocardial Infarction / prevention & control*
-
Myocardium / metabolism
-
Oxygen Consumption / drug effects
-
Postoperative Complications / mortality
-
Postoperative Complications / prevention & control*
-
Premedication
-
Randomized Controlled Trials as Topic
-
Survival Rate
Substances
-
Adrenergic beta-Antagonists